Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5).

In Dermatology
by ClinOwl February 18, 2021

Baricitinib, an oral, selective Janus kinase (JAK)1/JAK2 inhibitor, is being studied for moderate-to-severe atopic dermatitis (AD) in adults.To evaluate the efficacy and safety of baricitinib monotherapy in a North American […]

U.S. Burden of Skin and Subcutaneous Diseases Increasing

Can dermatology employers require employees to receive the COVID-19 vaccine?

THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

Expression of retinoid receptors in hand eczema.

S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5).